NCT00492830已完成1 期
A Phase 1, Open-label, Dose Escalation Study of the Humanized Monoclonal Antibody, TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors
Tracon Pharmaceuticals Inc.3 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2007年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 19
- 试验地点
- 3
- 主要终点
- Safety and tolerability will be evaluated
研究概览
简要总结
This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.
详细描述
In addition to safety, this study will also evaluate pharmacokinetics, tumor response, and anti-TRC093 antibody formation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A patient will be eligible for study participation only if all of the following criteria apply:
- •The patient has given informed consent.
- •The patient is willing and able to abide by the protocol.
- •The patient is at least 18 years old.
- •The patient has advanced cancer and is not eligible for treatment or no effective treatment exists.
- •Significant toxicities resulting from prior therapy must have recovered.
- •If the patient is a female of childbearing potential, she is using an acceptable/effective method of contraception.
- •If the patient is a female, she has had a negative serum pregnancy test within the past 30 days.
- •The patient has adequate ability to perform activities of daily living.
- •The patient has adequate organ function as assessed by laboratory tests
排除标准
- •A patient will not be eligible for study participation if any of the following criteria apply:
- •The patient weighs more than 264 lbs.
- •The patient has had a major surgical procedure, or significant injury within the past 28 days or there is an anticipation of the need for major surgery during the course of the study.
- •The patient has received treatment for their cancer, including radiation (minimal amount of localized radiation may be allowed), within the past 28 days.
- •The patient has known brain tumors.
- •The patient experienced blood clots within six months prior to study start.
- •The patient has a non-healing wound, ulcer or bone fracture.
- •The patient received recent thrombolytic or anticoagulant therapy.
- •The patient has an unstable medical condition or significant comorbid pathophysiology (e.g. active infection, poorly controlled diabetes, unstable angina, severe heart failure) that would interfere with his/her participation in the study.
- •The patient enrolled, or plans to enroll, in a concurrent treatment protocol with another investigational product.
- •The patient is receiving, or plans to receive, an anti-cancer therapy during the study with the exception of patients receiving chronic luteinizing hormone-releasing hormone (LHRH) agonists.
结局指标
主要结局
Safety and tolerability will be evaluated
时间窗: Through last patient last visit
Dose Limiting Toxicities
时间窗: 28 day evaluation period
次要结局
- Pharmacokinetics of TRC093 monoclonal antibody(Through last patient last visit)
- Number of responses by tumor type(Through last patient last visit)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)Human Papillomavirus InfectionNCT00988884Merck Sharp & Dohme LLC1,241
终止
1 期
Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273Infectious DiseaseCOVID-19NCT05420077RVAC Medicines (US), Inc.13
已完成
1 期
A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy AdultsHIVNCT05470400National Institute of Allergy and Infectious Diseases (NIAID)44
已完成
1 期
Study of the CD40 Agonistic Monoclonal Antibody APX005MUrothelial CarcinomaMSI-HHead and Neck CancerCancerMelanomaNSCLCNCT02482168Apexigen America, Inc.43
已完成
1 期
A Study of Intranasal ChAdOx1 nCOV-19CoronavirusNCT04816019University of Oxford42